Literature DB >> 28784674

Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection.

Adam Belley1, David Lalonde-Séguin2, Francis F Arhin2, Greg Moeck2.   

Abstract

There are limited therapeutic options to treat infections caused by vancomycin-resistant Enterococcus faecium (VREfm). The lipoglycopeptide oritavancin exhibits in vitro activity against this pathogen, although its utility against infections caused by VREfm has not been clinically established. In this study, the pharmacodynamic activity of free-drug levels associated with 12 mg/kg/day of daptomycin and a single 1,200-mg dose of oritavancin were determined against three VanA VREfm isolates in an in vitro pharmacokinetic/pharmacodynamic model.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Enterococcus faecium; daptomycin; lipoglycopeptide; oritavancin; vancomycin resistance

Mesh：

Substances：

Year:  2017        PMID： 28784674      PMCID： PMC5610485          DOI： 10.1128/AAC.01265-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints.

Authors:  Jose M Munita; Diana Panesso; Lorena Diaz; Truc T Tran; Jinnethe Reyes; Audrey Wanger; Barbara E Murray; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci.

Authors:  Debora Sweeney; Audrey Stoneburner; Dean L Shinabarger; Francis F Arhin; Adam Belley; Greg Moeck; Chris M Pillar
Journal:  J Antimicrob Chemother       Date:  2016-11-17       Impact factor: 5.790

3.  Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.

Authors:  Ashley D Hall; Molly E Steed; Cesar A Arias; Barbara E Murray; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

4.  Whole-genome analyses of Enterococcus faecium isolates with diverse daptomycin MICs.

Authors:  Lorena Diaz; Truc T Tran; Jose M Munita; William R Miller; Sandra Rincon; Lina P Carvajal; Aye Wollam; Jinnethe Reyes; Diana Panesso; Natalia L Rojas; Yousif Shamoo; Barbara E Murray; George M Weinstock; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

Review 5.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

6.  Direct fluorescence polarization assay for the detection of glycopeptide antibiotics.

Authors:  Linliang Yu; Meng Zhong; Yinan Wei
Journal:  Anal Chem       Date:  2010-08-15       Impact factor: 6.986

7.  Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.

Authors:  A Lefort; A Saleh-Mghir; L Garry; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

8.  Genetic basis for in vivo daptomycin resistance in enterococci.

Authors:  Cesar A Arias; Diana Panesso; Danielle M McGrath; Xiang Qin; Maria F Mojica; Corwin Miller; Lorena Diaz; Truc T Tran; Sandra Rincon; E Magda Barbu; Jinnethe Reyes; Jung H Roh; Elizabeth Lobos; Erica Sodergren; Renata Pasqualini; Wadih Arap; John P Quinn; Yousif Shamoo; Barbara E Murray; George M Weinstock
Journal:  N Engl J Med       Date:  2011-09-08       Impact factor: 91.245

9.  Multicenter study of high-dose daptomycin for treatment of enterococcal infections.

Authors:  Anthony M Casapao; Ravina Kullar; Susan L Davis; Donald P Levine; Jing J Zhao; Brian A Potoski; Debra A Goff; Christopher W Crank; John Segreti; George Sakoulas; Sara E Cosgrove; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

10.  Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.

Authors:  Adam Belley; Francis F Arhin; Ingrid Sarmiento; Hong Deng; Warren Rose; Greg Moeck
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191
View more
  4 in total

1.  Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin.

Authors:  Samira Dahesh; Brian Wong; Victor Nizet; George Sakoulas; Truc T Tran; Samuel L Aitken
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

2.  Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.

Authors:  Adam Belley; Francis F Arhin; Greg Moeck
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics.

Authors:  Christian Eckmann; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2021-11-22       Impact factor: 5.790

Review 4.  Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention.

Authors:  Esther Benamu; Stanley Deresinski
Journal:  F1000Res       Date:  2018-01-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.